Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- معلومة اضافية
- المصدر:
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
- بيانات النشر:
Original Publication: Basel, Switzerland : MDPI
- الموضوع:
- نبذة مختصرة :
Despite emerging evidence indicating that molecular SARS-CoV-2 tests performed on saliva have diagnostic sensitivity and specificity comparable to those observed with nasopharyngeal swabs (NPSs), most in vivo follow-up studies on the efficacy of drugs against SARS-CoV-2 have been performed on NPSs, not considering saliva as a possible alternative matrix. For this reason, in this study, we used, in parallel, saliva and NPS samples for the detection of SARS-CoV-2 by real-time RT-PCR in patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab as a treatment against SARS-CoV-2. Our results showed a good correlation between the NPS and saliva samples for each drug; moreover, comparable changes in the cycle threshold (Ct) levels in saliva and NPSs were observed both 7 days and 30 days after treatment, thus confirming that the saliva represents a good matrix for in vivo follow-up studies verifying the effectiveness of treatments against SARS-CoV-2.
Competing Interests: The authors declare no conflicts of interest.
- References:
Nat Med. 2022 Jun;28(6):1297-1302. (PMID: 35322239)
Expert Rev Mol Diagn. 2022 May;22(5):519-535. (PMID: 35763281)
Microorganisms. 2022 Jul 21;10(7):. (PMID: 35889194)
Br J Haematol. 2020 Jul;190(2):185-188. (PMID: 32557623)
Nature. 2022 Feb;602(7898):671-675. (PMID: 35016199)
Lancet Microbe. 2023 Oct;4(10):e837-e850. (PMID: 37516121)
Viruses. 2020 Oct 20;12(10):. (PMID: 33092065)
Blood. 2023 Jan 12;141(2):200-203. (PMID: 36332185)
Front Immunol. 2022 Apr 20;13:868020. (PMID: 35514955)
Nature. 2022 Feb;602(7898):657-663. (PMID: 35016194)
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101639. (PMID: 33636654)
J Allergy Clin Immunol Pract. 2023 Nov;11(11):3321-3333. (PMID: 37558163)
Front Public Health. 2021 May 21;9:589564. (PMID: 34150692)
J Infect. 2021 Mar;82(3):329-338. (PMID: 33549624)
Microbiol Spectr. 2023 Jun 15;11(3):e0532422. (PMID: 37093085)
Clin Microbiol Infect. 2019 Mar;25(3):372-378. (PMID: 29906597)
Int J Mol Sci. 2023 Mar 02;24(5):. (PMID: 36902277)
J Med Virol. 2021 Sep;93(9):5623-5625. (PMID: 33913552)
Microbiol Spectr. 2022 Dec 21;10(6):e0222922. (PMID: 36409097)
Lancet Respir Med. 2021 Jun;9(6):562-564. (PMID: 33887248)
Access Microbiol. 2022 May 20;4(5):acmi000366. (PMID: 36003360)
Ann Rheum Dis. 2021 Oct;80(10):1322-1329. (PMID: 34362747)
J Med Virol. 2023 Jan;95(1):e28186. (PMID: 36184918)
iScience. 2023 Apr 21;26(4):106413. (PMID: 36968074)
Antiviral Res. 2023 Jun;214:105609. (PMID: 37086978)
JAMA Intern Med. 2021 Mar 1;181(3):353-360. (PMID: 33449069)
Kidney Int. 2022 Aug;102(2):442-444. (PMID: 35618094)
Int J Infect Dis. 2022 Sep;122:401-404. (PMID: 35760381)
- Grant Information:
Program CCM 2020 Ricerca Corrente-Linea 1 on emerging and re-emerging infections Ministero della Salute
- Contributed Indexing:
Keywords: COVID-19 diagnosis; SARS-CoV-2; antiviral therapy; follow-up studies; molecular assay; monoclonal antibodies; saliva
- الرقم المعرف:
O3J8G9O825 (Ritonavir)
0 (Antiviral Agents)
0 (Antibodies, Monoclonal, Humanized)
0 (Drug Combinations)
2494G1JF75 (Lopinavir)
0 (lopinavir-ritonavir drug combination)
- الموضوع:
Date Created: 20240727 Date Completed: 20240727 Latest Revision: 20240729
- الموضوع:
20240729
- الرقم المعرف:
PMC11281700
- الرقم المعرف:
10.3390/v16071040
- الرقم المعرف:
39066203
No Comments.